Bristol-myers Squibb Compnay

Merck Patent Gmbh

Pride Mobility Products Corporation

Viiv Healthcare UK (no.5) Limited

Cancer Research Technology Limited

Bristol Meyers Squibb Company

Invenra Inc.

Viiv Healthcare UK Limited

Jonathan Harry Davis

Ray Camphausen

Dasa Lipovsek

Tracy S Mitchell

Rex A Parker

Amna Saeed-Kothe

Ginger Chao Rakestraw

Sharon T Cload

Doree F Sitkoff

Bowman Miao

Ching-Hsiung Frederick Lo

Katie A Russo

Chee Meng Low

Fabienne M Denhez

Michael Super

Mary Struthers

Priyanka Apurva Madia

Michael Louis Doyle

David Fabrizio

Michael L Gosselin

James S Huston

James Patrick Mulhern

Mark R Krystal

Pascal Andre Stein

Pascal André Stein

David L Wensel

Paul Charles Levesque

John C Carminati

David Nathan Laslo

Nicholas M Marshall

Glen Banks

David Laslo

Rex Parker

James Stafford Huston

A mobility vehicle may comprise a frame, a first pivot arm, a second pivot arm, and a suspension assembly. The first pivot arm may be coupled to the frame and coupled to a drive wheel. The second pivot arm may be coupled to the frame and coupled to a ground engaging caster wheel. The suspension assembly may be coupled to the frame. The suspension assembly may include a first spring assembly and a second spring assembly. The first spring assembly may be disposed about a first spring axis and coupled to the first pivot arm. The second spring assembly may be disposed about a second spring axis and coupled to the second pivot arm. The first spring axis and the second spring axis may be disposed relative to each other at an angle of no greater than about 150° when the mobility vehicle is operating on horizontal ground.

Mobility vehicle

Heterodimerizing domains with orthogonal mutations that drive heterodimerization, in particular heterodimerizing antibody CH3 domains, heterodimeric polypeptides comprising such heterodimerizing domains, and antibody constructs comprising such heterodimeric polypeptides, are provided.

Orthogonal mutations for heterodimerization

Disclosed herein are fusion proteins comprising: (a) a first polypeptide comprising Interleukin-2 (IL2); and (b) a second polypeptide, fused in frame to the first polypeptide, wherein the second polypeptide comprises an extracellular domain of Interleukin-2 Receptor alpha (IL2Rα), wherein IL2 or IL2Rα comprises at least one fewer glycosylation site compared to native IL2 or native IL2Rα. Methods of production and methods of therapeutic use of the fusion proteins are also disclosed.

Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use

The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.

Fibronectin based scaffold domain proteins that bind PCSK9

Disclosed herein are nucleic acid molecules, polypeptides, cells, vectors, and pharmaceutical compositions relating to miniaturized dystrophin. Methods of production and methods of therapeutic use of the miniaturized dystrophin are also disclosed.

Miniaturized dystrophins having spectrin fusion domains and uses thereof

Fibronectin type III (Fn3) binding domains having novel designs that are associated with reduced immunogenicity are provided. The application describes alternativeFn3 binding domains in which certain immunogenic regions are not modified when producing a binder in order to maintain recognition as a self antigen by the host organism. The application also describesFn3 binding domains in which HLA anchor regions have been destroyed thereby reducing the immunogenic contribution of the adjoining region. Also provided areFn3 domains having novel combinations of modified regions that can bind to a desired target with high affinity.

Fibronectin based scaffold proteins

A mobility vehicle may comprise a frame, a first pivot arm, a second pivot arm, and a suspension assembly. The first pivot arm may be coupled to the frame and coupled to a drive wheel. The second pivot arm may be coupled to the frame and coupled to a ground engaging caster wheel. The suspension assembly may be coupled to the frame. The suspension assembly may include a first spring assembly and a second spring assembly. The first spring assembly may be disposed about a first spring axis and coupled to the first pivot arm. The second spring assembly may be disposed about a second spring axis and coupled to the second pivot arm. The first spring axis and the second spring axis may be disposed relative to each other at an angle of no greater than about 150&#xb0; when the mobility vehicle is operating on horizontal ground.

Fibronectin binding domains with reduced immunogenicity

Disclosed herein are fusion proteins comprising: (a) a first polypeptide comprising Interleukin-2 (IL2); and (b) a second polypeptide, fused in frame to the first polypeptide, wherein the second polypeptide comprises an extracellular domain of Interleukin-2 Receptor alpha (IL2R&#x3b1;), wherein IL2 or IL2R&#x3b1; comprises at least one fewer glycosylation site compared to native IL2 or native IL2R&#x3b1;. Methods of production and methods of therapeutic use of the fusion proteins are also disclosed.

Interleukin-2/Interleukin-2 receptor alpha fusion proteins and methods of use

Anti-CD19 B4 antibodies with modified variable regions are disclosed. The modified anti-CD19 variable region polypeptides have alterations to one or more framework regions or complementarity determining regions of the heavy chain variable region or light chain variable region, thereby to reduce a T-cell response.

Anti-CD19 antibodies with reduced immunogenicity

The present invention relates to polypeptides which include tenth fibronectin type III domains (Fn3) that binds to serum albumin, with south pole loop substitutions. The invention further relates to fusion molecules comprising a serum albumin-bindingFn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.

Serum albumin-binding fibronectin type III domains

The invention is directed to polypeptides comprising a CD4 binding moiety, a gp41 binding moiety, a HIV fusion peptide inhibitor moiety and combinations thereof. More specifically, the present invention relates to polypeptides comprising a fibronectin-based scaffold domain protein that binds CD4, a fibronectin-based scaffold domain protein that binds the N17 domain of gp41, and a HIV fusion peptide inhibitor or combinations thereof. The invention also relates to the use of the innovative proteins in therapeutic applications to treat HIV.

Polypeptides targeting HIV fusion

Growing community of inventors

Auburndale, MA, United States of America

Jonathan Harry Davis